As MAPK pathway genetic mutations are frequently associated with MM, targeted therapies, that is, drugs to inhibit MAPK and MEK, are used, such as a combination of Vemurafenib with Cobimetinib, Dabrafenib (RAF inhibitor) with Trametinib (MEK1/2 inhibitor), or Encorafenib with Binimetininb. The gene discussed is MAP2K7; the disease is Miyoshi myopathy.